US FDA Authorize Keytruda Regimen as First-line Treatment for Cervical Cancer
The US FDA has now approved a combination of the chemotherapy and pembrolizumab, with or without the bevacizumab, for certain who are suffering from the persistent, metastatic or recurrent cervical cancer disease. This approval will be applied to the women having tumors that express the PD-L1 along with a combined positive score (CPS) of one […]
Continue Reading